Integra LifeSciences Holdings (IART)

Cash ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cash and cash equivalents	US$ in thousands	276,402	273,732	309,192	307,367	456,661	511,937	447,152	407,092	513,448	470,231	397,414	408,976	470,166	396,279	360,981	357,712	198,911	207,981	176,084	157,025
Short-term investments	US$ in thousands	32,694	19,938	20,200	15,659	0	13,111	4,369	—	—	—	—	—	—	—	—	—	—	—	—	—
Total current liabilities	US$ in thousands	306,980	355,712	377,496	282,293	320,906	304,452	295,596	315,833	340,021	332,858	318,756	412,301	401,013	255,146	212,415	246,485	331,309	302,641	315,111	288,106
Cash ratio		1.01	0.83	0.87	1.14	1.42	1.72	1.53	1.29	1.51	1.41	1.25	0.99	1.17	1.55	1.70	1.45	0.60	0.69	0.56	0.55

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($276,402K + $32,694K) ÷ $306,980K
= 1.01

The cash ratio of Integra Lifesciences Holdings Corp has shown a declining trend over the past four quarters, decreasing from 2.09 in Q3 2022 to 1.33 in Q4 2023. This indicates that the company may have less liquid cash available to cover its current liabilities in Q4 2023 compared to the previous quarters. A cash ratio of 1.33 means that for every dollar of current liabilities, the company has $1.33 of cash and cash equivalents on hand to meet its short-term obligations. While the ratio is above 1, suggesting the company is able to cover its short-term obligations, the decreasing trend warrants monitoring to ensure the company maintains sufficient liquidity to meet its financial obligations.